Monalizumab Biosimilar – Research Grade
ichorbio’s monalizumab biosimilar is for Research Use Only (RUO) and not for therapeutic use.
ichorbio’s RUO monalizumab biosimilar is available in the following sizes:
0.1mg, 5mg, 10mg, 20mg, 50mg
ichorbio regularly manufactures bulk multi-gram amounts of this biosimilar – please contact us for pricing.
KLRC1, CD159a, CD94
Detects human NKG2A. This non-therapeutic antibody uses the same variable region sequence as the therapeutic antibody monalizumab.
This recombinant protein was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.
RUO monalizumab is a blocking antibody that prevents the inhibition of CD8+ T cells and NK cell by tumor cells expressing HLA-E. By acting simultaneously on innate and adaptive immunity, monalizumab may re-establish a broad anti-tumor response.
1.0 – 5.0 mg/ml
Sterile, preservative-free, solution in PBS. BSA and Azide free.
>95% by SDS-PAGE and HPLC
≤ 1.0 EU/mg as determined by the LAL method
Monalizumab Biosimilar – Research Grade is stable for at least four (4) weeks when stored sterile at 2-8°C. For long term storage aseptically aliquot in working volumes without diluting and store at –80°C. Avoid Repeated Freeze Thaw Cycles.
Each investigator should determine their own optimal working dilution for specific applications.
ichorbio’s monalizumab biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.